Please login to the form below

Not currently logged in
Email:
Password:

New CEO for Grayling Germany

Frank Schönrock joins from Grünenthal
grayling Frank Schonrock

Frank Schönrock has left his role at pharma company Grünenthal to join the med comms agency Grayling Germany as CEO.

Schönrock joined Grünenthal in 2011 as VP of corporate communications before moving onto a global external communications role in his last year at the company. He was also a member of Grünenthal's global group leadership committee.

He now heads the German division of global comms network Grayling, overseeing a team of 40 consultants in Frankfurt, Düsseldorf and Hamburg.

Schönrock has previous agency experience having spent 12 year at Edelman Germany in several management positions, including co-heading the firms' office in Frankfurt.

“Frank is an exceptional talent and we are very proud to have him on board,” said Jan Simunek, Grayling's regional director for the DACH region, Central & Eastern Europe, Russia and CIS

“His background in healthcare, financial services, issues & crisis management and litigation PR will be particularly valuable as we look to grow the firm in Germany over the months and years to come.”

6th November 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics